Beyond Keytruda: Merck’s Oncology Pipeline Expansion Through M&A
Is Merck ready to face the looming patent cliff? Impact of Inflation Reduction Act (IRA) on Keytruda Inflation Reduction Act (IRA) was passed in 2022
Is Merck ready to face the looming patent cliff? Impact of Inflation Reduction Act (IRA) on Keytruda Inflation Reduction Act (IRA) was passed in 2022
Pembrolizumab, a monoclonal antibody marketed under the brand name Keytruda®, was Merck & Co’s highest-grossing product in FY 2023 with sales of about 25 billion
Chimeric Antigen Receptor (CAR)-T cell therapy, a groundbreaking form of immunotherapy harnessing a patient’s own T cells to combat cancer, has undergone remarkable advancements over
Secukinumab, an IL-17A antagonist, is marketed by Novartis under the brand name Cosentyx®. In 2023, Cosentyx® observed the sales of 5 billion dollars, inclusive of
The Pharmaceutical Industry of India plays a very important role around the globe. It is one of the largest generic medicine providers in the world.
Aragen Lifesciences to help Indian bioeconomy to reach $300 billion by 2030? India’s pharmaceutical Industry has long been dependent on Chinese-made Active Pharmaceutical Ingredients [API’s]
Welcome to World School of Life Sciences IP, a pioneer in empowering minds to dominate the ever-evolving landscape of patents and pharmaceutical innovations.
Copyright 2023 All right reserved by WSLI. Designed by Webpeckers.